Browse GNB2

Summary
SymbolGNB2
Nameguanine nucleotide binding protein (G protein), beta polypeptide 2
Aliases G protein, beta-2 subunit; guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 2; signal-transduc ......
Chromosomal Location7q21.3-q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, perinuclear region
Domain PF00400 WD domain
Function

Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction.

> Gene Ontology
 
Biological Process GO:0006457 protein folding
GO:0033762 response to glucagon
GO:0043434 response to peptide hormone
GO:0071375 cellular response to peptide hormone stimulus
GO:0071377 cellular response to glucagon stimulus
GO:0071417 cellular response to organonitrogen compound
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
Molecular Function GO:0003924 GTPase activity
GO:0005246 calcium channel regulator activity
GO:0016247 channel regulator activity
GO:0051020 GTPase binding
Cellular Component GO:0005765 lysosomal membrane
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
GO:0043209 myelin sheath
GO:0044297 cell body
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
hsa04062 Chemokine signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04713 Circadian entrainment
hsa04723 Retrograde endocannabinoid signaling
hsa04724 Glutamatergic synapse
hsa04725 Cholinergic synapse
hsa04726 Serotonergic synapse
hsa04727 GABAergic synapse
hsa04728 Dopaminergic synapse
Reactome R-HSA-418592: ADP signalling through P2Y purinoceptor 1
R-HSA-392170: ADP signalling through P2Y purinoceptor 12
R-HSA-1296041: Activation of G protein gated Potassium channels
R-HSA-991365: Activation of GABAB receptors
R-HSA-451326: Activation of Kainate Receptors upon glutamate binding
R-HSA-400042: Adrenaline,noradrenaline inhibits insulin secretion
R-HSA-445717: Aquaporin-mediated transport
R-HSA-3858494: Beta-catenin independent WNT signaling
R-HSA-4086398: Ca2+ pathway
R-HSA-390466: Chaperonin-mediated protein folding
R-HSA-373080: Class B/2 (Secretin family receptors)
R-HSA-6814122: Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
R-HSA-416482: G alpha (12/13) signalling events
R-HSA-418594: G alpha (i) signalling events
R-HSA-416476: G alpha (q) signalling events
R-HSA-418555: G alpha (s) signalling events
R-HSA-418597: G alpha (z) signalling events
R-HSA-392451: G beta
R-HSA-418217: G beta
R-HSA-1296059: G protein gated Potassium channels
R-HSA-202040: G-protein activation
R-HSA-397795: G-protein beta
R-HSA-977444: GABA B receptor activation
R-HSA-977443: GABA receptor activation
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-163359: Glucagon signaling in metabolic regulation
R-HSA-381676: Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
R-HSA-420092: Glucagon-type ligand receptors
R-HSA-109582: Hemostasis
R-HSA-997272: Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits
R-HSA-163685: Integration of energy metabolism
R-HSA-1296065: Inwardly rectifying K+ channels
R-HSA-1430728: Metabolism
R-HSA-392499: Metabolism of proteins
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-111885: Opioid Signalling
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-418346: Platelet homeostasis
R-HSA-1296071: Potassium Channels
R-HSA-500657: Presynaptic function of Kainate receptors
R-HSA-392851: Prostacyclin signalling through prostacyclin receptor
R-HSA-391251: Protein folding
R-HSA-422356: Regulation of insulin secretion
R-HSA-162582: Signal Transduction
R-HSA-392518: Signal amplification
R-HSA-372790: Signaling by GPCR
R-HSA-195721: Signaling by Wnt
R-HSA-456926: Thrombin signalling through proteinase activated receptors (PARs)
R-HSA-428930: Thromboxane signalling through TP receptor
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-112315: Transmission across Chemical Synapses
R-HSA-432040: Vasopressin regulates renal water homeostasis via Aquaporins
Summary
SymbolGNB2
Nameguanine nucleotide binding protein (G protein), beta polypeptide 2
Aliases G protein, beta-2 subunit; guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 2; signal-transduc ......
Chromosomal Location7q21.3-q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GNB2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolGNB2
Nameguanine nucleotide binding protein (G protein), beta polypeptide 2
Aliases G protein, beta-2 subunit; guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 2; signal-transduc ......
Chromosomal Location7q21.3-q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GNB2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.09; FDR: 0.02150 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolGNB2
Nameguanine nucleotide binding protein (G protein), beta polypeptide 2
Aliases G protein, beta-2 subunit; guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 2; signal-transduc ......
Chromosomal Location7q21.3-q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GNB2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0750.822
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3310.923
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1160.963
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4290.351
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0190.993
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9990.742
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.030.946
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2840.879
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2360.91
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3920.862
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2280.948
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1080.107
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GNB2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGNB2
Nameguanine nucleotide binding protein (G protein), beta polypeptide 2
Aliases G protein, beta-2 subunit; guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 2; signal-transduc ......
Chromosomal Location7q21.3-q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GNB2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGNB2
Nameguanine nucleotide binding protein (G protein), beta polypeptide 2
Aliases G protein, beta-2 subunit; guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 2; signal-transduc ......
Chromosomal Location7q21.3-q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GNB2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GNB2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGNB2
Nameguanine nucleotide binding protein (G protein), beta polypeptide 2
Aliases G protein, beta-2 subunit; guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 2; signal-transduc ......
Chromosomal Location7q21.3-q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GNB2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGNB2
Nameguanine nucleotide binding protein (G protein), beta polypeptide 2
Aliases G protein, beta-2 subunit; guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 2; signal-transduc ......
Chromosomal Location7q21.3-q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GNB2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGNB2
Nameguanine nucleotide binding protein (G protein), beta polypeptide 2
Aliases G protein, beta-2 subunit; guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 2; signal-transduc ......
Chromosomal Location7q21.3-q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GNB2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGNB2
Nameguanine nucleotide binding protein (G protein), beta polypeptide 2
Aliases G protein, beta-2 subunit; guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 2; signal-transduc ......
Chromosomal Location7q21.3-q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GNB2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.